Missing from the PBM hearings: value-based drug reimbursement
SUSAN WALSH/AP
In addition to oversight of pharmacy benefit manager rebates and payments, we need to improve the value of pharmaceutical spending in the U.S.
Suscribirse a:
Enviar comentarios (Atom)
No hay comentarios:
Publicar un comentario